Form 8K Current Report
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15 (d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): June 19, 2006
SIGA
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
0-23047
|
13-3864870
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
(Commission
file number)
|
(I.R.S.
employer
identification
no.)
|
|
420
Lexington Avenue, Suite 408
New
York, New York
(Address
of principal executive offices)
|
|
10170
(Zip
code)
|
Registrant’s
telephone number, including area code: (212) 672-9100
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
r
Written
communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
r
Soliciting
material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
r
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
r
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
1.01. Entry
Into a Material Definitive Agreement.
On
June
19, 2006, SIGA Technologies, Inc., a Delaware corporation (“SIGA”) issued the
third and final of three 8% Notes (the “Note”) in favor of PharmAthene, Inc.
(“Pharmathene”) as required pursuant to that certain Bridge Note Purchase
Agreement (the “Purchase Agreement”), dated March 20, 2006, between SIGA and
Pharmathene (a copy of the Purchase Agreement is publicly available as an
exhibit to SIGA’s Form 8-K filed on March 22, 2006).
The
Note
is for a principal amount of $1,000,000 and will be payable on the earliest
of
(x) June 19, 2008 (the “Maturity Date”), (y) the closing of a Qualified
Financing (as defined in the Purchase Agreement) or (z) a Sale Event (as defined
in the Purchase Agreement). In the case of a default under the Note, payment
of
the Note will be accelerated such that the entire unpaid principal amount of
the
Note, and all accrued and unpaid interest thereon, shall become immediately
due
and payable in full.
A
copy of
the Note is attached hereto as Exhibit 10.1, which is incorporated into this
Item 1.01 by reference.
Item
2.03. Creation
of a Direct Financial Obligation or an Obligation under an Off- Balance Sheet
Arrangement.
See
Item
1.01 above, which is incorporated into this Item 2.03 by reference, for a
description of the Note.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits
|
Exhibit
No.
|
Description
|
|
10.1
|
8%
Note, dated June 18, 2006, by SIGA Technologies, Inc., in favor of
PharmAthene, Inc.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
SIGA
TECHNOLOGIES,
INC.
By:
/s/
Thomas N. Konatich
Name:
Thomas
N.
Konatich
Title:
Acting
Chief Executive Officer and Chief Financial Officer
Date: June
20,
2006